Skip to content
Trial Eligibility
Menu

Breast Cancer Clinical Trials near Chicago, IL

104 studies for Breast Cancer are recruiting at 487 sites within 50 miles of Chicago, Illinois, according to ClinicalTrials.gov data processed .

Distances are city-level approximations. See all Breast Cancer trials in the US or all trials near Chicago.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Breast Cancer studies enrolling near Chicago

Showing the 50 nearest of 104 studies.
  1. Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

    NCT05929768

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Advocate Illinois Masonic Medical Center (Chicago, IL); John H Stroger Jr Hospital of Cook County (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    50 sites within 50 mi
  2. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    NCT05879926

    • Phase 3
    • Ages 18 to 60 years
    • Sex: Female

    Nearest sites: Advocate Illinois Masonic Medical Center (Chicago, IL); John H Stroger Jr Hospital of Cook County (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    45 sites within 50 mi
  3. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

    NCT05812807

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Advocate Illinois Masonic Medical Center (Chicago, IL); John H Stroger Jr Hospital of Cook County (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    40 sites within 50 mi
  4. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    NCT06876714

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Advocate Illinois Masonic Medical Center (Chicago, IL); John H Stroger Jr Hospital of Cook County (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    39 sites within 50 mi
  5. De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

    NCT04852887

    • Phase 3
    • Ages 50 to 70 years
    • Sex: All

    Nearest sites: Advocate Illinois Masonic Medical Center (Chicago, IL); John H Stroger Jr Hospital of Cook County (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    38 sites within 50 mi
  6. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    NCT05564377

    • Phase 2
    • Ages Any age
    • Sex: All

    Nearest sites: Advocate Illinois Masonic Medical Center (Chicago, IL); John H Stroger Jr Hospital of Cook County (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    30 sites within 50 mi
  7. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    NCT06058377

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Advocate Illinois Masonic Medical Center (Chicago, IL); Mount Sinai Hospital Medical Center (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    29 sites within 50 mi
  8. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    NCT05334069

    • Observational
    • Ages 40 to 75 years
    • Sex: All
    • Accepts healthy volunteers

    Nearest sites: Advocate Illinois Masonic Medical Center (Chicago, IL); John H Stroger Jr Hospital of Cook County (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    18 sites within 50 mi
  9. Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

    NCT06418204

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Advocate Illinois Masonic Medical Center (Chicago, IL); John H Stroger Jr Hospital of Cook County (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    17 sites within 50 mi
  10. E-Mindfulness Approaches for Living After Breast Cancer

    NCT06748222

    • Phase 3
    • Ages 18 to 50 years
    • Sex: All

    Nearest sites: Northwestern University (Chicago, IL); Rush MD Anderson Cancer Center (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    16 sites within 50 mi
  11. Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

    NCT07391774

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Northwestern Medicine Cancer Center Old Irving Park (Chicago, IL); Northwestern University (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    11 sites within 50 mi
  12. A Study of Sigvotatug Vedotin in Advanced Solid Tumors

    NCT04389632

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: The University Of Chicago (Chicago, IL); UChicago Medicine - River East (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    10 sites within 50 mi
  13. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

    NCT05633654

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Northwestern Medicine (Chicago, IL); Rush University Medical Center (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 50 mi
  14. MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

    NCT03053193

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of Illinois at Chicago (Chicago, IL); Affiliated Oncologists (Oak Lawn, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  15. Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

    NCT06380751

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Research Site (Chicago, IL); Research Site (Evanston, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  16. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

    NCT06492616

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Northwestern Memorial Hospital (Chicago, IL); RUSH MD Anderson Cancer Center (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  17. QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

    NCT06551116

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of Chicago Medical Center (Chicago, IL); University of Chicago Medicine-Orland Park (Orland Park, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  18. A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

    NCT07310420

    • Phase 1
    • Ages 18 to 55 years
    • Sex: Female

    Nearest sites: University of Illinois at Chicago (Chicago, IL); NorthShore University Health System - Evanston Hospital (Evanston, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  19. PRE-ISPY Phase I/II Oncology Platform Program

    NCT05868226

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: The University of Chicago Medicine Comprehensive Cancer Center (Chicago, IL); UChicago Medicine Orland Park (Orland Park, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  20. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

    NCT06293898

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of Chicago Medicine (Chicago, IL); University of Illinois Cancer Center (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  21. Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

    NCT06500481

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Northwestern University (Chicago, IL); Northwestern Medicine Cancer Center Warrenville (Warrenville, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  22. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    NCT01042379

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of Chicago (Chicago, IL); Loyola University (Maywood, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  23. S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

    NCT03418961

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: John H Stroger Jr Hospital of Cook County (Chicago, IL); Loyola University Medical Center (Maywood, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  24. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

    NCT05005403

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of Chicago Medical Center /ID# 276271 (Chicago, IL); University of Illinois Hospital and Health Sciences System /ID# 251750 (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  25. Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

    NCT05232916

    • Phase 3
    • Ages 18 to 100 years
    • Sex: All

    Nearest sites: Northwestern University - Northwestern Memorial Hospital (Chicago, IL); City of Hope - Cancer Center Chicago (Zion, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  26. Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

    NCT06062498

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Northwestern University (Chicago, IL); University of Chicago (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  27. Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

    NCT06072612

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Northwestern University (Chicago, IL); Northwest Cancer Center (Dyer, IN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  28. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

    NCT06084481

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Northwestern Medicine - Northwestern Memorial Hospital /ID# 257378 (Chicago, IL); University of Chicago Medical Center /ID# 258197 (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  29. Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

    NCT06184750

    • Phase 2
    • Ages 18 to 55 years
    • Sex: Female

    Nearest sites: Northwestern University (Chicago, IL); University of Illinois College of Medicine - Chicago (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  30. A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

    NCT06369285

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: The University of Chicago (Chicago, IL); University of Illinois Cancer Center (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  31. SMP-3124LP in Adults With Advanced Solid Tumors

    NCT06526819

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Northwestern Medicine Cancer Center (Chicago, IL); The University of Chicago (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  32. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    NCT06638307

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of Chicago Medical Center (Chicago, IL); University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center) (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  33. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    NCT06982521

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Chicago, IL); Rush University Medical Center (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  34. A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

    NCT07174336

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: City of Hope, Chicago (Chicago, IL); Accellacare of Duly (Lisle, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  35. Feasibility and Acceptibility of a Multi-site Trial of Time Restircted Eating During Chemotheraply for Breast Cancer.

    NCT07387445

    • Interventional
    • Ages 25 to 99 years
    • Sex: Female

    Nearest sites: Robert H. Lurie Comprehensive Cancer Center (Chicago, IL); University of Illinois Chicago (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  36. Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer

    NCT00898131

    • Observational
    • Ages Any age
    • Sex: Female

    Nearest site: Robert H. Lurie Comprehensive Cancer Center at Northwestern University (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  37. Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

    NCT02620852

    • Interventional
    • Ages 30 to 74 years
    • Sex: Female
    • Accepts healthy volunteers

    Nearest site: University of Chicago (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  38. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    NCT03452774

    • Observational
    • Ages Any age
    • Sex: All

    Nearest site: Massive Bio SYNERGY-AI site (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  39. A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer

    NCT03729115

    • Interventional
    • Ages 25 years and older
    • Sex: Female
    • Accepts healthy volunteers

    Nearest site: University Of Chicago Medicine Comprehensive Cancer Center (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  40. Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

    NCT03990896

    • Phase 2
    • Ages 18 years and older
    • Sex: Female

    Nearest site: Northwestern University (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  41. A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

    NCT04300556

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Northwestern Memorial Hospital (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  42. Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

    NCT04373564

    • Phase 4
    • Ages 18 to 64 years
    • Sex: All

    Nearest site: University of Chicago Medical Center (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  43. Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

    NCT04468061

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: University of Chicago Medical Center (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  44. Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

    NCT04841148

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: University of Chicago (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  45. Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

    NCT04886531

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: University of Illinois Cancer Center (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  46. BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer

    NCT04891068

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: University of Illinois Cancer Center (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  47. ATEMPT 2.0: Adjuvant T-DM1 vs TH

    NCT04893109

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: The University of Chicago Medical Center (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  48. CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

    NCT05029999

    • Phase 1
    • Ages 18 to 99 years
    • Sex: All

    Nearest site: University of Chicago Comprehensive Cancer Center (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  49. A Study of NX-1607 in Adults With Advanced Malignancies

    NCT05107674

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: University of Chicago (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  50. First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

    NCT05216432

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: University of Chicago Medical Center (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi

FAQ

Common questions

What is a clinical trial?
A clinical trial is a research study in people that tests a medical, surgical or behavioral intervention, such as an investigational drug or device. Observational studies are also listed: they collect information without assigning a treatment. Read how clinical trials work.
Is there compensation for joining a Breast Cancer clinical trial?
Compensation for time and travel may be available, but it varies by study and some studies offer none. The amount and schedule are reviewed by an ethics board and described in the consent form. See compensation in clinical trials.
How do I check if I'm eligible?
Each study lists age, sex and other inclusion and exclusion criteria on its ClinicalTrials.gov record. Only the study team can confirm eligibility, usually through a screening call or visit. Talk with your own doctor before joining any study.

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.